NECLIFE Share Price Performance
₹14.03
-15.69 (-52.79%)
Price ₹14.03
Share Price₹14.03
NECLIFE Community Narratives
There are no narratives available yet.
Recent NECLIFE News & Updates
No updates
Nectar Lifesciences Limited Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -5.07
- Gross Margin
- 18.08%
- Net Profit Margin
- -6.81%
- Debt/Equity Ratio
- 60.9%
Nectar Lifesciences Limited Competitors
About NECLIFE
- Founded
- 1995
- Employees
- 1686
- CEO
- WebsiteView website
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Indian Market Performance
- 7 Days: -0.8%
- 3 Months: 4.5%
- 1 Year: -2.1%
- Year to Date: -1.3%
In the last week, the market has been flat, with a notable exception in the Healthcare sector dropping 3.5%. In line with that, the market has also been flat over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading